FibroGen, Inc (FGEN) Shares Bought by Strs Ohio

Strs Ohio increased its holdings in shares of FibroGen, Inc (NASDAQ:FGEN) by 15.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 164,900 shares of the biopharmaceutical company’s stock after acquiring an additional 21,900 shares during the period. Strs Ohio owned about 0.23% of FibroGen worth $8,871,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in FibroGen during the 2nd quarter worth approximately $128,000. Ameritas Investment Partners Inc. grew its position in FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares during the last quarter. SG Americas Securities LLC grew its position in FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 412 shares during the last quarter. Amalgamated Bank bought a new stake in FibroGen during the 2nd quarter worth approximately $237,000. Finally, BNP Paribas Arbitrage SA grew its position in FibroGen by 589.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 6,327 shares during the last quarter. Institutional investors and hedge funds own 47.37% of the company’s stock.

In other FibroGen news, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $40.74, for a total transaction of $81,480.00. Following the sale, the director now owns 30,000 shares of the company’s stock, valued at $1,222,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Pat Cotroneo sold 2,851 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $49.45, for a total transaction of $140,981.95. Following the sale, the vice president now directly owns 157,405 shares in the company, valued at approximately $7,783,677.25. The disclosure for this sale can be found here. In the last three months, insiders sold 552,828 shares of company stock worth $27,774,395. 14.90% of the stock is currently owned by insiders.

WARNING: “FibroGen, Inc (FGEN) Shares Bought by Strs Ohio” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/10/29/fibrogen-inc-fgen-shares-bought-by-strs-ohio.html.

FibroGen, Inc (FGEN) opened at 55.90 on Friday. The stock has a 50 day moving average price of $53.84 and a 200-day moving average price of $38.36. FibroGen, Inc has a 1-year low of $15.60 and a 1-year high of $60.15. The firm’s market cap is $3.98 billion.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million during the quarter, compared to the consensus estimate of $34.80 million. Equities research analysts forecast that FibroGen, Inc will post ($1.81) EPS for the current year.

A number of research analysts have commented on FGEN shares. Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research report on Friday, July 21st. Jefferies Group LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. Mizuho started coverage on FibroGen in a research report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price objective on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Finally, BidaskClub lowered FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. FibroGen presently has an average rating of “Buy” and an average price target of $65.67.

FibroGen Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

What are top analysts saying about FibroGen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for FibroGen Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit